Brazil · Advertising framework
Influencer marketing for prescription medicines in Brazil
General market orientation, not campaign clearance. Research scope and dates
Key restrictions and conditions
RDC 96 needs a current judicial and regulatory status check
Regulator guidance
RDC 96/2008 remains a source requiring a specific enforceability review. ANVISA’s TAP 40/2026 records prolonged litigation limiting practical application and opens a new regulatory process, listed as ongoing in the retrieved record. Opening this process is not a replacement regulation or proof that all old provisions have ceased to apply.
Do not describe the STJ litigation, the STF proceedings or the 2026 review as a blanket permission for medicine advertising. Retain the statutory product restrictions and check the current operative court orders, affected parties and exact RDC provision for the campaign. A final judicial resolution was not established in this follow-up.
Sources: STJ Informativo 821: REsp 2.035.645-DF; ANVISA opens a review of food and medicine advertising rules, August 2026; ANVISA prohibits public advertising of Semavy, September 2026; TAP 40/2026 — medicine advertising rule review
Product and service rules
Prescription medicine advertising is restricted
Legal requirement — paraphrased
Prescription-medicine promotion is directed to the eligible prescribing or dispensing professionals under the applicable rules. Publicly accessible internet information is not an unrestricted advertising route. Check professional access controls and the stricter rules for controlled medicines before distribution.
Sources: ANVISA RDC 96/2008: medicine advertising; Lei 6.360/1976; ANVISA prohibits public advertising of Semavy, September 2026
Channel rules
Check the complete consumer-facing message
Regulator guidance
Consumer advertising must be identifiable and must not be misleading or abusive, including through omission. Keep the factual, technical and scientific basis for the message. Review service promises, product claims, price conditions and imagery together; an influencer label does not remove these obligations.
Review the 2026 CONAR influencer framework
Regulator guidance
CONAR’s 2026 guide addresses advertising identification, truthful presentation, restricted sectors and campaign governance. Use it alongside the applicable ANVISA and professional rules; self-regulatory disclosure does not create permission to endorse a prescription medicine or promise a clinical result.
Sources: 2026 Guide to Marketing and Advertising by Digital Influencers
Health information has a sensitive-data regime
Regulator guidance
ANPD identifies health information as sensitive personal data under the LGPD. Determine an applicable Article 11 condition for that processing rather than relying automatically on an ordinary Article 7 marketing basis. Review patient stories, list building, tracking and sharing separately.
Sources: ANPD frequently asked questions
Brief the creator on the permitted message
Editorial recommendation
Check whether endorsements are permitted for the selected offer before contracting a creator. Record payments, gifts and affiliate links; specify the required advertising identification, approved claims, editing controls and takedown process.
Campaign workflow
Prescription Medicines: prepare the review
Editorial recommendation
Identify the exact authorised medicine and prescription status. Resolve the public-promotion restriction or permitted route before developing creative. Separate medicine promotion from neutral disease information and healthcare-service advertising.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Identify the exact authorised medicine and prescription status.
- Resolve the public-promotion restriction or permitted route before developing creative.
- Separate medicine promotion from neutral disease information and healthcare-service advertising.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- CFO patient-image conditions and the IVD-specific RDC 830/2023 route are now documented. The final effect of RDC 96 litigation remains unverified. Actual court orders, state/municipal licences, pharmacy codes, product warning assets and the legal basis for direct marketing still require a campaign review.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
Prescription-medicine advertising through influencer collaborations in Brazil starts with a legal eligibility decision. Establish whether the proposed consumer message is permitted, restricted to limited information or confined to a professional route before developing benefit and risk statements.
Creator selection and commercial disclosure are only part of an influencer review. Examine the person's role, the spoken and visual claims, supplied benefits and the final publication together; a personal experience can still communicate a regulated claim.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Federal ANVISA and professional advertising baseline; local licences and professional scope require individual checks. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- STJ Informativo 821: REsp 2.035.645-DF
- ANVISA opens a review of food and medicine advertising rules, August 2026
- ANVISA prohibits public advertising of Semavy, September 2026
- TAP 40/2026 — medicine advertising rule review
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- ANVISA RDC 96/2008: medicine advertising
Check consolidated amendments and the effect of any applicable judicial decision on the particular provision.
- Lei 6.360/1976
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Consumer Protection Code, Lei 8.078/1990
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- 2026 Guide to Marketing and Advertising by Digital Influencers
Self-regulatory guidance, not a statute. Announcement checked; detailed case-specific execution still needs the full operative guide.
- ANPD frequently asked questions
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
From framework to action
Local expertise in Brazil
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Brazil.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.